TRVI Stock Forecast & Price Target

Trevi Therapeutics Inc. has demonstrated a robust financial position with a cash balance of $194.9 million, expected to sustain operations into 2028, which underpins the continued development of its investigational therapy, Haduvio. Recent operational advancements, including steady progress towards a Phase 3 program for chronic cough in idiopathic pulmonary fibrosis, alongside positive results from various Phase 2 trials, highlight the potential market demand for its therapies. Additionally, the narrowing net loss of $11.8 million compared to the previous year's $13.2 million reflects improved financial management amid expanding opportunities within the chronic cough market, forecasted to generate substantial revenue potential exceeding $4.5 billion.

Trevi Therapeutics Inc. reported a decrease in Q3 R&D expenses to $10.1 million, attributed to the wind-down of multiple clinical trials, which raises concerns about the progress of its investigational therapy, Haduvio. Key risks to the company's outlook include potential delays in clinical development, market competition, and the need for future capital raises as profitability remains elusive. Furthermore, with approximately 13% of shares held by a single institutional investor, there exists heightened vulnerability to adverse market movements and potential volatility, which could adversely affect Trevi's stock value.